ARQL - ArQule Has A Solid Pipeline And The Ability To Gain Speedy Approval Makes It A Must Watch
ArQule (ARQL) is an important biotech to watch, that's because it had a huge update on a mid-stage study, showing positive results in patients with rare diseases known as PIK3CA-related Overgrowth Spectrum or PROS and proteus syndrome ((PS)). This is a solid speculative biotech. The reason why is because its focus is on targeting specific genetic mutations associated with cancer. This creates a more targeted approach to treat cancer that is caused by genetic mutations. Even better than that, I believe that the biotech has the opportunity to create massive gains for investors.